We are live on
!
Find out more
ACP
Acuta Capital Partners Portfolio holdings
AUM
$143M
1-Year Est. Return
773.18%
This Fund
S&P 500
This Quarter
Est. Return
+22.48%
1 Year Est. Return
+773.18%
3 Year Est. Return
+7,269.42%
5 Year Est. Return
+14,284.66%
10 Year Est. Return
+1,769,765.59%
AUM
$143M
AUM Growth
+$1.74M
(+1.2%)
Cap. Flow
-$14.9M
Cap. Flow
% of AUM
-10.35%
Top 10 Holdings %
Top 10 Hldgs %
73.75%
Holding
32
New
5
Increased
9
Reduced
6
Closed
9
Avg Time Held Equity + Options
3.8
quarters
Top 10 Avg Time Held Equity + Options
2.4
quarters
Top 20 Avg Time Held Equity + Options
3.9
quarters
Avg Time Held Equity only
3.8
quarters
Top 10 Avg Time Held Equity only
2.4
quarters
Top 20 Avg Time Held Equity only
3.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ArriVent BioPharma
AVBP
|
+$6.45M |
| 2 |
Whitehawk Therapeutics
WHWK
|
+$5.31M |
| 3 |
4D Molecular Therapeutics
FDMT
|
+$4.95M |
| 4 |
Avalyn Pharma
AVLN
|
+$3.32M |
| 5 |
Artiva Biotherapeutics
ARTV
|
+$2.37M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Terns Pharmaceuticals
TERN
|
+$26.1M |
| 2 |
Oculis Holding
OCS
|
+$2.61M |
| 3 |
Revolution Medicines
RVMD
|
+$2.54M |
| 4 |
IDEAYA Biosciences
IDYA
|
+$1.61M |
| 5 |
Bright Minds Biosciences
DRUG
|
+$1.51M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Praxis Precision Medicines
PRAX
$6.76B
| $27.7M | 19.32% |
82,796
-2,105
| -2% | -$666K |
2023 Q2
12 quarters
|
|
|
2
Whitehawk Therapeutics
WHWK
$176M
| $21.5M | 14.96% |
4,685,912
+1,275,510
| +37% | +$5.31M |
2021 Q3
19 quarters
|
|
3
Tango Therapeutics
TNGX
$3.81B
| $12.2M | 8.52% |
390,949
-50,882
| -12% | -$1.26M |
2025 Q4
2 quarters
|
|
4
Sutro Biopharma
STRO
$183M
| $8.97M | 6.25% |
270,251
+826
| +0.3% | +$25.8K |
2025 Q4
2 quarters
|
|
|
5
ArriVent BioPharma
AVBP
$778M
| $7.6M | 5.29% |
+218,694
| New | +$6.45M |
2026 Q2
0 quarters
|
|
|
6
4D Molecular Therapeutics
FDMT
$676M
| $6.75M | 4.71% |
+507,801
| New | +$4.95M |
2026 Q2
0 quarters
|
|
|
7
Bright Minds Biosciences
DRUG
$520M
| $6.51M | 4.54% |
92,745
-19,251
| -17% | -$1.51M |
2024 Q4
6 quarters
|
|
8
Ocular Therapeutix
OCUL
$1.59B
| $5.23M | 3.64% |
532,481
-59,627
| -10% | -$540K |
2023 Q4
10 quarters
|
|
9
Erasca
ERAS
$5.16B
| $4.86M | 3.39% |
265,199
-89,376
| -25% | -$1.28M |
2026 Q1
1 quarter
|
|
10
Surrozen
SRZN
$278M
| $4.5M | 3.14% |
173,395
+548
| +0.3% | +$15.1K |
2025 Q1
5 quarters
|
|
11
argenx
ARGX
$52.3B
| $4.37M | 3.04% |
4,705
+15
| +0.3% | +$12.4K |
2024 Q2
8 quarters
|
|
12
MoonLake Immunotherapeutics
MLTX
$895M
| $4.2M | 2.93% |
215,652
+23,892
| +12% | +$433K |
2025 Q4
2 quarters
|
|
13
Design Therapeutics
DSGN
$618M
| $4.09M | 2.85% |
282,564
+136,664
| +94% | +$1.7M |
2025 Q4
2 quarters
|
|
14
Minerva Neurosciences
NERV
$120M
| $3.94M | 2.74% |
709,500
| – | – |
2025 Q4
2 quarters
|
|
15
Taysha Gene Therapies
TSHA
$1.19B
| $3.83M | 2.67% |
561,808
+122,344
| +28% | +$724K |
2025 Q2
4 quarters
|
|
|
16
Avalyn Pharma
AVLN
$1.05B
| $3.79M | 2.64% |
+115,000
| New | +$3.32M |
2026 Q2
0 quarters
|
|
17
Avalo Therapeutics
AVTX
$647M
| $3.44M | 2.4% |
186,308
+125,500
| +206% | +$1.98M |
2026 Q1
1 quarter
|
|
18
Amylyx Pharmaceuticals
AMLX
$3.45B
| $3.02M | 2.1% |
168,115
+17,048
| +11% | +$264K |
2025 Q3
3 quarters
|
|
|
19
Artiva Biotherapeutics
ARTV
$294M
| $2.53M | 1.76% |
+260,416
| New | +$2.37M |
2026 Q2
0 quarters
|
|
20
Compass Therapeutics
CMPX
$153M
| $1.3M | 0.91% |
595,213
-253,863
| -30% | -$749K |
2025 Q3
3 quarters
|
|
21
United Therapeutics
UTHR
$23.3B
| $1.21M | 0.84% |
2,224
| – | – |
2025 Q3
3 quarters
|
|
22
Contineum Therapeutics
CTNM
$324M
| $1.03M | 0.72% |
+63,095
| New | +$827K |
2026 Q2
0 quarters
|
|
23
LB Pharmaceuticals
LBRX
$1.13B
| $939K | 0.65% |
28,919
| – | – |
2025 Q3
3 quarters
|
|
|
24
CALL
IDEAYA Biosciences
IDYA
$3.33B
| – | – |
-350
| Closed | -$1.17M | – |
|
|
25
IDEAYA Biosciences
IDYA
$3.33B
| – | – |
-48,234
| Closed | -$1.61M | – |
|
Similar funds
FPC
WWM
AVA
BOM
PWM
FF
JPT
BJF
Acuta Capital Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Acuta Capital Partners held 32 positions worth $143M, up 1.2% from $142M the previous quarter. Its ten largest holdings account for 74% of the portfolio.
Acuta Capital Partners withdrew a net $14.9M in Q2 2026, closing 9 positions and reducing 6 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $26.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.
Against the trend, Acuta Capital Partners opened a new position in ArriVent BioPharma worth $7.6M.
- Acuta Capital Partners's largest Q2 2026 buy was ArriVent BioPharma: 218,694 shares worth $7.6M.
- Acuta Capital Partners added most to Whitehawk Therapeutics in Q2 2026, an estimated $5.31M increase.
- Acuta Capital Partners's biggest Q2 2026 reduction was Bright Minds Biosciences, cutting an estimated $1.51M.
- Acuta Capital Partners fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $26.1M.
- Acuta Capital Partners's ten largest holdings make up 74% of its $143M portfolio in Q2 2026.
- Acuta Capital Partners opened 5 new positions and closed 9 in Q2 2026.
- Acuta Capital Partners's portfolio value rose 1.2% quarter-over-quarter to $143M.
Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.